



## C4 Therapeutics Appoints Andrea Armstrong as Chief Administrative Officer

September 22, 2016 11:00 AM EDT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--[C4 Therapeutics](#) (C4T) today announced that Andrea Armstrong has been promoted to Chief Administrative Officer. She joined C4T as a human resources consultant in January, 2016 and transitioned to full-time as the Senior Vice President of Human Resources in June, 2016. Ms. Armstrong has led the human resources function with a focus on talent acquisition efforts and will now also assume responsibility for facilities and laboratory operations, environmental health and safety, IT and office management, and internal communications.

"Andrea has been integral to the growth of C4T to this point," said Andrew Phillips, Ph.D., President and Chief Scientific Officer of C4 Therapeutics. "In addition to Andrea's talents in human resources, her extensive organizational development and operational experience will bring much to our next phase of growth. I look forward to working with her in this expanded role."

Prior to joining C4T, Ms. Armstrong was Chief Human Resources Officer and Vice President of Administration at the New York Genome Center, where she led all aspects of human resources, facilities, EHS, IT and office management. Earlier in her career, Ms. Armstrong worked for Infinity Pharmaceuticals, where she led full cycle recruiting efforts for the company. Prior to Infinity, she had 15 years of experience as an executive recruiter as Vice President at D.P. Parker & Associates, a boutique retained search firm specializing in the technology, biotech and pharmaceutical industries.

Ms. Armstrong holds a B.A. in international relations from Tufts University and an M.A. in environmental health from Boston University.

### About C4 Therapeutics

C4 Therapeutics is a private biotechnology company developing a new class of drugs based on Targeted Protein Degradation (TPD) to address a broad range of life-threatening and life-impairing diseases. C4T's Degronimid™ platform uses small molecule drugs to direct the machinery of the ubiquitin-proteasome system to selectively degrade disease-relevant proteins for therapeutic benefit. Leveraging this distinctive mechanism provides new opportunities to target traditionally difficult to treat diseases and drug resistance. The wide-ranging potential of the Degronimid approach underpins C4T's internal drug discovery programs as well as strategic partnerships with leading global pharmaceutical and biotechnology firms.

More information about C4 Therapeutics is available at [www.C4Therapeutics.com](http://www.C4Therapeutics.com).

### Contacts

#### Media Contact:

MacDougall Biomedical Communications

Kari Watson, 781-235-3060

[kwatson@macbiocom.com](mailto:kwatson@macbiocom.com)

or

Casey R. Doucette, Ph.D., 781-235-3060

[cdoucette@macbiocom.com](mailto:cdoucette@macbiocom.com)